GSK, Vir Biotech to expand COVID-19 research partnership for other diseases

As a part of the deal to research and develop monoclonal antibody
treatments for influenza and other respiratory illnesses, GSK will
make a further $120 million equity investment in Vir and an additional
upfront payment of $225 million.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/gsk-vir-biotech-to-expand-covid-19-research-partnership-for-other-diseases/articleshow/81062795.cms

Comments

Popular posts from this blog

Lupin, Aurobindo units recall products in US market

MAHE Manipal Research Fellow Jobs – Biotech / Mol Bio / Microbiology Apply

Data Analyst Jobs – Life Sciences Apply at Cognizant